Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Almirall seeks nod for...

    Almirall seeks nod for tildrakizumab in Europe: Sun Pharma

    Written by supriya kashyap kashyap Published On 2017-03-26T11:11:49+05:30  |  Updated On 26 March 2017 11:11 AM IST
    Almirall seeks nod for tildrakizumab in Europe: Sun Pharma

    New Delhi : Drug major Sun Pharmaceutical Industries said Spain-based Almirall S.L has sought regulatory approval from the European Medicines Agency for a new drug, tildrakizumab.


    The drug is being evaluated for the treatment of moderate-to-severe plaque psoriasis, the two companies said in a statement.


    In July 2016, Almirall entered into a licensing agreement with Sun Pharma for the development and commercialisation of tildrakizumab in Europe, it added.


    The filing includes efficacy and safety data from the pivotal Phase III clinical trials that included over 1,800 patients across more than 200 clinical sites, the statement said.


    "The filing of tildrakizumab in Europe is a significant step forward for healthcare providers as many patients are still suffering from the disease," Almirall CEO Eduardo Sanchiz said.


    Tildrakizumab adds a novel biologic treatment option to "our extensive and innovative portfolio, strengthening our position as a leading dermatology player," he added.


    Under the terms of the pact, Sun Pharma will continue to lead other indications, for which Almirall will have the right to primary negotiation. In addition, Almirall will be able to lead European studies, and participate in larger global clinical studies for psoriasis, the statement said.


    Shares of Sun Pharma were trading 0.23 per cent higher at Rs 705.45 per scrip in afternoon trade on BSE.

    AlmirallEduardo SanchizEuropean Medicines AgencySun PharmaTildrakizumab
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok